Based on this structure for the immune complex, the important observation that this mAb binds α-linked TF antigen, but not β-TF, yielding tumor specificity, could be rationalized on the basis that a β-linkage at the reducing terminus would result in overlaps between the aglycon and several residues in CDR L1, including, TyrL31, SerL32, and AsnL33 (Fig. 4). This evidence concerns the gene TF and neoplasm.